Antibacterial Resistance Leadership Group: Open for business

Henry F. Chambers, John Bartlett, Robert A. Bonomo, Christine Chiou, Sara Cosgrove, Heather R. Cross, Robert S. Daum, Michele Downing, Scott R. Evans, Jane Knisely, Barry N. Kreiswirth, Ebbing Lautenbach, Brenda S. Mickley, Robin Patel, Melinda M. Pettigrew, Keith A. Rodvold, Brad Spellberg, Vance G. Fowler

Research output: Contribution to journalArticle

Abstract

Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.

Original languageEnglish (US)
Pages (from-to)1571-1576
Number of pages6
JournalClinical Infectious Diseases
Volume58
Issue number11
DOIs
StatePublished - Jun 1 2014

Fingerprint

Research
National Institute of Allergy and Infectious Diseases (U.S.)
Infection
Disease Resistance
Gram-Positive Bacteria
Gram-Negative Bacteria
Research Design
Public Health
Clinical Studies

Keywords

  • Antibacterial resistance
  • ARLG
  • Clinical research
  • Clinical trials
  • Leadership Group

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Medicine(all)

Cite this

Chambers, H. F., Bartlett, J., Bonomo, R. A., Chiou, C., Cosgrove, S., Cross, H. R., ... Fowler, V. G. (2014). Antibacterial Resistance Leadership Group: Open for business. Clinical Infectious Diseases, 58(11), 1571-1576. https://doi.org/10.1093/cid/ciu132

Antibacterial Resistance Leadership Group : Open for business. / Chambers, Henry F.; Bartlett, John; Bonomo, Robert A.; Chiou, Christine; Cosgrove, Sara; Cross, Heather R.; Daum, Robert S.; Downing, Michele; Evans, Scott R.; Knisely, Jane; Kreiswirth, Barry N.; Lautenbach, Ebbing; Mickley, Brenda S.; Patel, Robin; Pettigrew, Melinda M.; Rodvold, Keith A.; Spellberg, Brad; Fowler, Vance G.

In: Clinical Infectious Diseases, Vol. 58, No. 11, 01.06.2014, p. 1571-1576.

Research output: Contribution to journalArticle

Chambers, HF, Bartlett, J, Bonomo, RA, Chiou, C, Cosgrove, S, Cross, HR, Daum, RS, Downing, M, Evans, SR, Knisely, J, Kreiswirth, BN, Lautenbach, E, Mickley, BS, Patel, R, Pettigrew, MM, Rodvold, KA, Spellberg, B & Fowler, VG 2014, 'Antibacterial Resistance Leadership Group: Open for business', Clinical Infectious Diseases, vol. 58, no. 11, pp. 1571-1576. https://doi.org/10.1093/cid/ciu132
Chambers, Henry F. ; Bartlett, John ; Bonomo, Robert A. ; Chiou, Christine ; Cosgrove, Sara ; Cross, Heather R. ; Daum, Robert S. ; Downing, Michele ; Evans, Scott R. ; Knisely, Jane ; Kreiswirth, Barry N. ; Lautenbach, Ebbing ; Mickley, Brenda S. ; Patel, Robin ; Pettigrew, Melinda M. ; Rodvold, Keith A. ; Spellberg, Brad ; Fowler, Vance G. / Antibacterial Resistance Leadership Group : Open for business. In: Clinical Infectious Diseases. 2014 ; Vol. 58, No. 11. pp. 1571-1576.
@article{78a1f44a78654771aa1185f932c26eb5,
title = "Antibacterial Resistance Leadership Group: Open for business",
abstract = "Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.",
keywords = "Antibacterial resistance, ARLG, Clinical research, Clinical trials, Leadership Group",
author = "Chambers, {Henry F.} and John Bartlett and Bonomo, {Robert A.} and Christine Chiou and Sara Cosgrove and Cross, {Heather R.} and Daum, {Robert S.} and Michele Downing and Evans, {Scott R.} and Jane Knisely and Kreiswirth, {Barry N.} and Ebbing Lautenbach and Mickley, {Brenda S.} and Robin Patel and Pettigrew, {Melinda M.} and Rodvold, {Keith A.} and Brad Spellberg and Fowler, {Vance G.}",
year = "2014",
month = "6",
day = "1",
doi = "10.1093/cid/ciu132",
language = "English (US)",
volume = "58",
pages = "1571--1576",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Antibacterial Resistance Leadership Group

T2 - Open for business

AU - Chambers, Henry F.

AU - Bartlett, John

AU - Bonomo, Robert A.

AU - Chiou, Christine

AU - Cosgrove, Sara

AU - Cross, Heather R.

AU - Daum, Robert S.

AU - Downing, Michele

AU - Evans, Scott R.

AU - Knisely, Jane

AU - Kreiswirth, Barry N.

AU - Lautenbach, Ebbing

AU - Mickley, Brenda S.

AU - Patel, Robin

AU - Pettigrew, Melinda M.

AU - Rodvold, Keith A.

AU - Spellberg, Brad

AU - Fowler, Vance G.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.

AB - Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.

KW - Antibacterial resistance

KW - ARLG

KW - Clinical research

KW - Clinical trials

KW - Leadership Group

UR - http://www.scopus.com/inward/record.url?scp=84900456166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900456166&partnerID=8YFLogxK

U2 - 10.1093/cid/ciu132

DO - 10.1093/cid/ciu132

M3 - Article

C2 - 24610430

AN - SCOPUS:84900456166

VL - 58

SP - 1571

EP - 1576

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -